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Abstract
 
Efferent activity in the vagus nerve can prevent endotoxin-induced shock by attenuating tumor
necrosis factor (TNF) synthesis. Termed the “cholinergic antiinflammatory pathway,” inhibi-
tion of TNF synthesis is dependent on nicotinic 
 
 
 
-bungarotoxin-sensitive acetylcholine recep-
tors on macrophages. Vagus nerve firing is also stimulated by CNI-1493, a tetravalent guanyl-
hydrazone molecule that inhibits systemic inflammation. Here, we studied the effects of
pharmacological and electrical stimulation of the intact vagus nerve in adult male Lewis rats
subjected to endotoxin-induced shock to determine whether intact vagus nerve signaling is
required for the antiinflammatory action of CNI-1493. CNI-1493 administered via the in-
tracerebroventricular route was 100,000-fold more effective in suppressing endotoxin-induced
TNF release and shock as compared with intravenous dosing. Surgical or chemical vagotomy
rendered animals sensitive to TNF release and shock, despite treatment with CNI-1493, indi-
cating that an intact cholinergic antiinflammatory pathway is required for antiinflammatory effi-
cacy in vivo. Electrical stimulation of either the right or left intact vagus nerve conferred signif-
icant protection against endotoxin-induced shock, and specifically attenuated serum and
myocardial TNF, but not pulmonary TNF synthesis, as compared with sham-operated animals.
Together, these results indicate that stimulation of the cholinergic antiinflammatory pathway
by either pharmacological or electrical methods can attenuate the systemic inflammatory re-
sponse to endotoxin-induced shock.
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Introduction
 
TNF, high mobility group B (HMGB)1, IL-1, and other
inflammatory cytokines released by cells of the innate im-
mune system mediate the systemic response to infection,
injury, and endotoxemia. The magnitude and duration of
the inflammatory response can influence survival because
an unrestrained inflammatory response mediates lethal
shock and tissue injury (1, 2). The central nervous system
(CNS)
 
*
 
 has an important antiinflammatory role in prevent-
ing the development of lethal systemic inflammation. For
instance, proinflammatory mediators (e.g., LPS, TNF, IL-1)
activate afferent neural pathways in the vagus nerve that
stimulate release of pituitary adrenocorticotrophic hormone;
the resultant increase in serum corticosteroids suppresses cy-
tokine release to prevent excessive inflammation (3, 4). In
addition to this sensory function of the vagus nerve in sys-
temic inflammation, we recently described an efferent or
motor vagus neural mechanism by which acetylcholine, the
principal vagus nerve neurotransmitter, inhibits cytokine
release from resident tissue macrophages, termed the “cho-
linergic antiinflammatory pathway” (5).
Acetylcholine, the principle neurotransmitter of the va-
gus nerve, binds nicotinic cholinergic receptors on resident
macrophages, and this receptor–ligand interaction inhibits
the synthesis of TNF at a posttranscriptional level (5). Vago-
tomy renders animals exquisitely sensitive to endotoxin;
vagotomized animals produce significantly more TNF and
are significantly more sensitive to endotoxin-induced hy-
potension (5). Direct electrical stimulation of the efferent
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vagus nerve confers significant protection against the devel-
opment of endotoxin-induced shock and prevents the re-
lease of TNF in tissue and serum (5). The vagus nerve is
distributed throughout the reticuloendothelial system, and
since neural signaling is rapid, it now appears that CNS-
derived motor output through the cholinergic antiinflam-
matory pathway is uniquely positioned to modulate the de-
velopment of systemic inflammation and shock.
CNI-1493, an experimental therapeutic now undergo-
ing testing in Phase II clinical trials for Crohn’s disease, is a
tetravalent guanylhydrazone inhibitor of macrophage acti-
vation that prevents the phosphorylation of p38 mitogen-
activated protein kinase (MAPK; references 6–8). During
the course of describing the activity of CNI-1493 in cere-
bral ischemia, we observed that direct application into the
cerebral ventricles suppressed cerebral TNF synthesis (9).
As further controls in these experiments, the effect of in-
tracerebral CNI-1493 on peripheral endotoxin responses
was also studied, and surprisingly, CNI-1493 administered
via the intracerebroventricular (i.c.v.) route attenuated the
production of systemic TNF. Administration of CNI-1493
directly stimulated neural activity in the cholinergic antiin-
flammatory pathway (10). Together, these studies suggested
the intriguing hypothesis that the TNF-inhibiting activity
of CNI-1493 in vivo might require signaling via the cho-
linergic antiinflammatory pathway. Here we show that ad-
ministration of CNI-1493 inhibits systemic TNF release
and TNF synthesis in tissues during endotoxemia through a
mechanism that is dependent upon an intact cholinergic
anti-inflammatory pathway.
 
Materials and Methods
 
Animals.
 
Adult male Lewis rats (280–300 g; Charles River
Laboratories) were housed at 25
 
 
 
C on a 12 h light/dark cycle.
Standard rat chow and water were freely available. All animal ex-
periments were performed in accordance with the National Insti-
tutes of Health (NIH) Guidelines under protocols approved by the
Institutional Animal Care and Use Committee of North Shore
University Hospital and New York University Medical School.
 
I.C.V. Injections.
 
Rats were anesthetized with ketamine
(10%) in xylazine and placed in a stereotatic head frame (Stoelting
Co.). The incisor bar was adjusted until the plane defined by the
lambda and bregma was parallel to the base plate. The needle of a
Hamilton syringe (25 ml) was stereotactically guided into lateral
ventricle (0.8 mm posterior to bregma, 1.5 mm lateral to midline,
3.0 mm below the dura). CNI-1493 was dissolved in sterile en-
dotoxin-free water and administered .2 min. The location of
i.c.v. injections was confirmed by histological examination of the
brain after the experiment.
 
Tissue-specific Distribution of CNI-1493.
 
14
 
C-labeled CNI-
1493 (87 
 
 
 
Ci/mg; ChemSyn Laboratories) was dissolved in ster-
ile pyrogen-free water and administered via either intravenous (1
mg/kg) or i.c.v. (100 ng/kg) routes. After 1 h, rats underwent
transcardial perfusion with 250 ml of NaCl (0.9%) followed by
100 ml of paraformaldehyde (4% in 0.1 M Dulbecco’s phosphate-
buffered saline, pH 7.3). Radioactivity in tissue samples was
counted by a liquid scintillation system (Beckman LS 7800; Beck-
man Instruments, Inc.), and the content of CNI-1493 calculated
by comparison with 
 
14
 
C standards.
 
Endotoxin Shock.
 
The left common iliac artery and right
common femoral vein were cannulated with a 23-gauge intrave-
nous catheter in anesthetized rats. The arterial catheter was con-
nected to a blood pressure transducer and recorder (Model MP
100 acquisition system; Biopac Systems) for continuous registra-
tion of mean arterial blood pressure (MABP) and heart rate
(HR). Endotoxin (LPS, 
 
Escherichia coli
 
 0111:B4; Sigma-Aldrich)
was dissolved in sterile pyrogen-free saline at stock concentrations
of 10 mg/ml, and sonicated for 30 min immediately before use
for each experiment in the doses indicated. Blood was collected
from the right femoral vein 1 h after LPS administration, allowed
to clot for 2 h at room temperature, then centrifuged for 20 min
at 1,500 
 
g
 
. Serum samples were stored at 20
 
 
 
C before analysis.
 
Vagotomy and Atropine Blockade.
 
Anesthetized rats were sub-
jected to bilateral cervical vagotomy or sham surgery as described
previously (5). A ventral cervical midline incision was used to ex-
pose both vagus trunks, which were ligated with 4–0 silk sutures
and divided. In sham-operated animals both vagus nerve trunks
were exposed and isolated from surrounding tissue but not
transected. Atropine (Sigma-Aldrich) was dissolved in sterile sa-
line and administered intravenously at a dose of 1 mg/kg/h; con-
trol animals received a comparable volume of saline.
 
Electrical Stimulation of Intact Vagus Nerve.
 
Where indicated,
the vagus nerve was exposed and isolated from surrounding tissue
with parafilm. Intact vagus nerves were stimulated with constant
voltage at either 1V (2 ms, 5 Hz) or 5V (2 ms, 5 Hz) for 10 min
intervals before and after LPS injection, for a total of 20 continu-
ous min, using bipolar platinum electrodes connected to the
stimulation module. Rats were subjected to either left vagus
stimulation, right vagus stimulation, or sham operation. MABP,
HR, and respiratory rate were recorded every 5 min, beginning
30 min before, and ending 150 min after LPS injection. Blood
was collected from the right femoral vein after 180 min and se-
rum TNF measured. At the completion of monitoring, animals
were killed, the heart, liver, and lung rapidly excised, rinsed of
blood, homogenized by polytron (Brinkman) in homogenization
buffer (PBS containing 0.05% Triton X-100 and a protease in-
hibitor cocktail, pH 7.2, 4
 
 
 
C), and sonicated for 10 min. Ho-
mogenates were centrifuged at 12,000 
 
g 
 
for 10 min, and TNF
measured using the L929 bioassay. Liver, lung, and heart TNF
were normalized to the protein concentration in the sample.
 
Statistical Analysis.
 
All data in the figures, tables, and text are
expressed as mean 
 
 
 
SEM for at least 4–5 animals per condition.
Student’s 
 
t
 
 test was used to compare mean values between groups
(
 
P 
 
  
 
0.05).
 
Results
 
I.C.V. CNI-1493 Is 100,000-fold More Effective Than In-
travenous CNI-1493 at Attenuating Endotoxin-induced Hy-
potension and Serum TNF.
 
Vehicle-treated endotoxemic
rats developed significant hypotension and increased serum
TNF levels within 1 h after exposure to a lethal dose of
LPS (Fig. 1). Pretreatment with intravenous CNI-1493 sig-
nificantly and dose–dependently inhibited serum TNF re-
lease (vehicle control 
 
 
 
 10 
 
 
 
 2 ng TNF/ml vs. 300 
 
 
 
g
CNI-1493/kg, intravenous 
 
 
 
 2 
 
 
 
 0.3 ng TNF/ml; 
 
P 
 
 
 
0.05) and prevented the development of LPS-induced hy-
potension (vehicle control 
 
 
 
 14 
 
  
 
5% of starting MABP
vs. 300 
 
 
 
g CNI-1493/kg, intravenous 
 
 
 
 86 
 
 
 
 7% of start-
ing MABP; 
 
P 
 
  
 
0.05) (Fig. 1). The lowest intravenous 
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CNI-1493 dose tested (100 
 
 
 
g/kg) failed to prevent TNF
release (vehicle control 
 
 
 
 10
 
  
 
 2 ng TNF/ml vs. 100 
 
 
 
g
CNI-1493/kg, intravenous 
 
 
 
 10 
 
 
 
 1 ng TNF/ml; 
 
P 
 
 
 
0.05) or hypotension (vehicle control 
 
 
 
 14 
 
  
 
5% of start-
ing MABP vs. 100 
 
 
 
g CNI-1493/kg, intravenous 
 
 
 
 21 
 
 
 
9% of starting MABP; 
 
P 
 
  
 
0.05). i.c.v. administration of a
100-fold dilution of this ineffective intravenous dose signif-
icantly attenuated serum TNF release (vehicle control 
 
 
 
10 
 
 
 
 2 ng TNF/ml vs. 1,000 ng CNI-1493/kg, i.c.v. 
 
 
 
1 
 
  
 
0.2 ng TNF/ml; 
 
P 
 
  
 
0.05) and protected against the
development of hypotension (vehicle control 
 
 
 
 23 
 
 
 
 9%
of starting MABP vs. 1,000 ng CNI-1493/kg, i.c.v. 
 
 
 
107 
 
 
 
 9% of starting MABP; 
 
P 
 
  
 
0.05) (Fig. 1). Surpris-
ingly, much lower i.c.v. doses of CNI-1493 (10, 1.0, and
0.1 ng CNI-1493/kg) conferred significant protection against
the development of endotoxin-induced shock (vehicle con-
trol 
 
 
 
 23 
 
 
 
 9% of starting MABP vs. 10 ng CNI-1493/kg,
i.c.v. 
 
 
 
 97 
 
 
 
 8% of starting MABP, 
 
P
 
   
 
0.05; 1.0 ng
CNI-1493/kg, i.c.v. 
 
 
 
 115 
 
  
 
6% of starting MABP, 
 
P 
 
 
 
0.05; and 0.1 ng CNI-1493/kg, i.c.v. 
 
 
 
 61 
 
 
 
 4% of start-
ing MABP, 
 
P 
 
  
 
0.05) and inhibited serum TNF (vehicle
control 
 
 
 
 10 
 
  
 
1 ng TNF/ml vs. 10 ng CNI-1493/kg,
i.c.v. 
 
 
 
 2 
 
  
 
0.3 ng TNF/ml, 
 
P 
 
  
 
0.05; 1.0 ng CNI-1493/
kg, i.c.v. 
 
 
 
 2
 
   
 
0.4 ng TNF/ml, 
 
P 
 
  
 
0.05; and 0.1 ng
CNI-1493/kg, i.c.v. 
 
 
 
 5 
 
  
 
1 ng TNF/ml, 
 
P 
 
  
 
0.05) (Fig.
1). Comparison of dose–response curves constructed from
data obtained after CNI-1493 was given via either intrave-
nous or i.c.v. routes revealed that the latter route was at
least 100,000 times more effective in preventing TNF re-
lease and shock (Fig. 1), suggesting that the CNS partici-
pates in the systemic antiinflammatory action of CNI-1493
during endotoxemia.
 
Intravenous CNI-1493 Accumulates in Brain.
 
To deter-
mine the tissue distribution of CNI-1493 after systemic
dosing, we measured radioactivity in rat tissues 1 h after in-
travenous administration of 
 
14
 
C-labeled CNI-1493 (1 mg/
Figure 1. CNI-1493 (intravenous or i.c.v.) inhibits endotoxin-induced hypotension and attenuates serum TNF. (A) CNI-1493 was given intrave-
nously in the doses shown; endotoxin (15 mg/kg, intravenously) was administered 60 min later. After 1 h, blood was collected via carotid artery catheter,
and serum prepared for TNF assays. (B) CNI-1493 was given i.c.v. in the doses shown; endotoxin (15 mg/kg, intravenously) was administered 60 min
later. After 1 h, blood was collected via carotid artery catheter, and serum prepared for TNF assays. (C) Intravenous injection of CNI-1493 60 min before
endotoxin exposure prevented endotoxic shock. 1 h after exposure to a lethal dose of LPS (15 mg/kg), vehicle-treated endotoxemic rats developed sig-
nificant LPS-induced hypotension. Intravenous administration of CNI-1493, in doses of 300 or 500 mg/kg, given 60 min before endotoxin exposure
significantly prevented the development of LPS-induced hypotension. (D) i.c.v. injection of CNI-1493 60 min before endotoxin exposure prevented en-
dotoxin-induced shock. 1 h after exposure to a lethal dose of LPS (15 mg/kg), vehicle-treated endotoxemic rats developed significant LPS-induced hy-
potension. i.c.v. doses of CNI-1493 (1,000, 10, 1.0, and 0.1 ng/kg) given 60 min before endotoxin exposure significantly prevented the development of
LPS-induced hypotension. 
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kg). After transcardiac perfusion to minimize nonspecific
binding, the highest levels of radioactivity were observed in
the spleen, liver, kidney, lungs, and gastrointestinal tract.
Lesser accumulation was observed in brain, skin, muscle,
and heart (Table I). Although peripheral organs did not ac-
cumulate significant radioactivity after i.c.v. injection of
 
14
 
C-CNI-1493, significant radioactive uptake persisted in
brain (Table I). The amount of radioactivity detected in
brain after i.c.v. administration of 100 ng/kg of 
 
14
 
C-CNI-
1493 was comparable to that observed after intravenous ad-
ministration of 1 mg/kg of 
 
14
 
C-CNI-1493. Each of these
dosing regimens suppressed endotoxin-induced TNF and
shock (Fig. 1), so that brain drug levels achieved after intra-
venous dosing with a higher dose were comparable to those
achieved with direct i.c.v. application of a lesser, but phar-
macologically active, dose of CNI-1493. The i.c.v. doses
that effectively inhibited systemic inflammatory responses
were too low to reach detectable levels in peripheral tissues,
suggesting that the CNS participates in mediating the sys-
temic antiinflammatory mechanisms of CNI-1493.
 
The Protective Effects of CNI-1493 Are Abolished by Surgical
or Chemical Vagotomy.
 
To determine whether an intact
cholinergic antiinflammatory pathway is required for inhi-
bition of TNF and protection from endotoxin-induced
shock by i.c.v. or intravenous CNI-1493, animals were
subjected to either surgical or chemical vagotomy. Surgical
vagotomy eliminated the protective effects of i.c.v. CNI-
1493 against LPS-induced hypotension (sham surgery plus
1.0 ng CNI-1493/kg, i.c.v. 
 
 
 
 83 
 
  
 
5% of starting MABP
vs. surgical vagotomy plus 1.0 ng CNI-1493/kg, i.c.v. 
 
 
 
35 
 
 
 
 6% of starting MABP, 
 
P 
 
  
 
0.05). Surgical vagotomy
also eliminated the protective effect of intravenous CNI-
1493 against endotoxin-induced shock (500 
 
 
 
g CNI-
1493/kg, intravenous plus sham vagotomy 
 
 
 
 89
 
   
 
4 vs.
surgical vagotomy plus 500 
 
 
 
g CNI-1493/kg, intrave-
nous 
 
 
 
 55 
 
  
 
11% of starting MABP; 
 
P 
 
  
 
0.05), indicating
that the protective effects of CNI-1493, whether adminis-
tered into the brain or the peripheral circulation, require an
intact vagus nerve. Surgical vagotomy also significantly at-
tenuated the protective effects of intracerebral CNI-1493
against LPS-induced TNF release as compared with sham
surgery (sham surgery plus 1.0 ng CNI-1493/kg, i.c.v. 
 
 
 
 1 
 
 
 
0.2 ng TNF/ml vs. vagotomy plus 1.0 ng CNI-1493/kg,
i.c.v. 
 
 
 
 18 
 
  
 
4 ng TNF/ml; 
 
P 
 
  
 
0.05) (Fig. 2). Similar
observations were made after administration of atropine, an
antagonist of cholinergic signaling, because atropine abol-
ished the protective effect of i.c.v. CNI-1493 against LPS-
induced hypotension (vehicle plus 1.0 ng CNI-1493/kg,
i.c.v. 
 
 
 
 93 
 
  
 
11% of starting MABP vs. atropine plus 1.0
ng CNI-1493/kg, i.c.v. 
 
 
 
 50 
 
 
 
 3% of starting MABP; 
 
P 
 
 
 
0.05). Atropine abolished the protective effect of i.c.v.
CNI-1493 against LPS-induced TNF release (vehicle plus
1.0 ng CNI-1493/kg, i.c.v. 
 
 
 
 1 
 
 
 
 0.2 ng TNF/ml vs. 1
mg atropine/kg/h plus 1.0 ng CNI-1493/kg, i.c.v. 
 
 
 
 10 
 
 
 
3 ng TNF/ml; 
 
P 
 
  
 
0.05) (Fig. 2). Considered with the
previously described observations that CNI-1493 stimulates
increased vagus nerve activity when administered in vivo
(10), these results indicate that cholinergic vagus neural sig-
nals mediate systemic protection against endotoxin-induced
TNF and hypotension.
 
Intact Vagus Nerve Stimulation Protects Against Endotoxin-
induced Hypotension and Endotoxin-induced Shock.
 
Vagus
nerve stimulators are used clinically for the treatment of
seizure disorders and depression, but the effects of this
treatment applied to intact vagus nerves on the develop-
ment of systemic inflammatory responses are unknown
(11). The above observations with a pharmacological vagus
nerve stimulator (CNI-1493) predict that electrical stimula-
tion of the vagus nerve might recapitulate the antiinflam-
matory action of CNI-1493. We electrically stimulated in-
tact vagus nerves and observed that this procedure
significantly prevented the development of hypotension
during endotoxemia (Fig. 3). Stimulation with either 1 V
or 5 V impulses at 2 ms intervals (5 Hz) prevented the de-
velopment of significant hypotension (control 
 
 
 
 51 
 
  
 
1%
of starting MABP vs. 1 V stimulation 
 
 
 
 96 
 
  
 
2% of start-
 
Table I.
 
Distribution of 
 
14
 
C-labeled CNI-1493 in Rat Tissues 60 min After Intravenous (1 mg/kg) and Intracerebroventricular
(100 ng/kg) Injections
 
Tissue/organ
CNI-1493 after intravenous
(1 mg/kg injection) g/mg tissue
CNI-1493 after i.c.v.
(100 ng/kg) injection ng/mg tissue
Blood 4.5
 
   
 
1.3 ND
Brain 1.8 
 
  
 
0.3 1.6 
 
  
 
0.6
Heart 3.3 
 
  
 
0.7 ND
Intestine 12.6 
 
  
 
5.1 ND
Kidney 18.6 
 
  
 
1.9 ND
Liver 19.7 
 
  
 
5.4 ND
Lung 13.0 
 
  
 
5.0 ND
Muscle 2.7 
 
  
 
1.1 ND
Skin 8.5 
 
  
 
2.5 ND
Spleen 21.8 
 
  
 
2.1 ND 
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ing MABP, 
 
P 
 
  
 
0.05; and 5 V stimulation 
 
 
 
 101   1% of
starting MABP, P   0.05) (Fig. 3). HR did not increase
significantly in nonstimulated endotoxemic animals, despite
the development of hypotension. Stimulation of the vagus
nerve, however, was associated with a significant increase
in HR; the increase in HR was voltage stimulus dependent
(sham HR   195   15 bpm vs. 1 V vagus stimulation  
304   12 bpm, P   0.05, and 5 V vagus stimulation  
342   11 bpm, P   0.05) (Fig. 3). To assess whether the
right and left vagus nerves contribute a differential protec-
tive effect, we measured blood pressure and HR in animals
after separately stimulating either nerve. As demonstrated
in Fig. 3, we observed no significant difference between
right and left cervical vagus nerve stimulation. Cardiac and
pulmonary TNF synthesis has been implicated in the de-
velopment of endotoxin-induced myocardial depression
and acute lung injury (12, 13). To address the specificity of
stimulating intact vagus nerves on inhibition of TNF, we
measured cardiac and pulmonary TNF during lethal endo-
toxemia. Vagus nerve stimulation (5 V, 2 ms, 5 Hz) during
lethal endotoxemia significantly attenuated cardiac TNF
levels (unstimulated   251   61 ng TNF/g protein vs.
stimulated   107   29 ng TNF/g protein; P   0.05), but
failed to inhibit pulmonary TNF levels (Fig. 4), indicating
that cholinergic anti-inflammatory pathway inhibition of
TNF in liver (5) and heart is specific.
Discussion
CNI-1493 is a tetravalent guanylhydrazone that inhibits
phosphorylation of p38 MAPK and suppresses proinflam-
matory cytokine release from monocytes and macrophages
(6–8). Systemic administration of CNI-1493 is effective in
the treatment of experimental endotoxemia, sepsis, allergic
encephalitis, cerebral ischemia, and arthritis (6, 9, 14–16).
Administration of CNI-1493 to cancer patients undergoing
IL-2 therapy significantly attenuated systemic TNF (17).
The present results now indicate that an intact cholinergic
antiinflammatory pathway is required for the antiinflamma-
tory action of CNI-1493 in vivo. Here, i.c.v. CNI-1493
attenuated endotoxin-induced proinflammatory cytokine
release and shock at doses that are ineffective via the intra-
venous route. Moreover, surgical or chemical (atropine)
vagotomy completely abolished the antiinflammatory ef-
fects of CNI-1493. Thus, an intact cholinergic antiinflam-
matory pathway is required for the macrophage-deactivat-
ing effects of CNI-1493 given via either the intracerebral
or intravenous routes. Indeed, it now appears that the pri-
mary antiinflammatory mechanism of systemically adminis-
tered CNI-1493 is centrally mediated.
Previous studies implicated the CNS in preferentially
mediating the antiinflammatory action of  -melanocyte–
stimulating hormone ( -MSH; reference 18), and the non-
Figure 2. Chemical or surgical vagotomy blocks the protective action of intrace-
rebral CNI-1493. (A) Effects of bilateral cervical vagotomy vs. sham surgery on the
action of i.c.v. CNI-1493 (ng/kg) during endotoxemia, expressed as the percentage
of starting MABP. CNI-1493 (1.0 ng/kg) was administered i.c.v., followed 60 min
later by endotoxin (15 mg/kg, intravenously). Note that surgical vagotomy elimi-
nated the protective effects of 1.0 ng CNI-1493/kg, i.c.v. against LPS-induced hy-
potension. (B) Effects of intravenous saline treatment (control) vs. atropine block-
ade on the action of i.c.v. administered CNI-1493 during endotoxemia, expressed
as the percentage of starting MABP. CNI-1493 (1.0 ng/kg, i.c.v.) was administered
to animals treated with atropine (1 mg/kg/h, intravenously) to block vagus nerve
activity. Note that chemical vagotomy abolished the protective effect of i.c.v.
CNI-1493 against LPS-induced hypotension. (C) Serum TNF levels after i.c.v.
CNI-1493 injection 60 min after LPS infusion. On the left, all animals received an
i.c.v. injection of vehicle. On the right, animals received CNI-1493 (1.0 ng/kg,
i.c.v.). In both panels, “Ctrl” refers to animals that received atropine vehicle (sa-
line), while “Sham” identifies those animals in which the vagus nerves were exposed, but not surgically divided. Note that chemical vagotomy and surgical
vagotomy both significantly attenuated the protective effects of CNI-1493 (1.0 ng/kg, i.c.v.) against LPS-induced TNF release as compared with vehicle.786 Cholinergic Antiinflammatory Pathway Suppresses Inflammation
steroidal antiinflammatory drugs lysine acetylsalicylate and
sodium salicylate (19). Systemically administered  -MSH
inhibits activation of NF- B (20), a transcription factor that
is required for the transcription of TNF (21). Significantly
lower doses of centrally administered  -MSH modulate
cytokine-induced cutaneous inflammation (19), through a
sympathetic neural route that is acetylcholine independent
and  2-adrenergic receptor dependent (22, 23). Consid-
ered with the present findings, it appears that the CNS is
positioned to rapidly and effectively modulate acute innate
immune responses by innervation of immune tissues. The
identities of the CNS receptor(s) for CNI-1493, and the
central neural fiber tract(s) that mediate activation of the cho-
linergic antiinflammatory pathway are unknown. CNI-1493
is an effective inhibitor of the phosphorylation of p38
MAPK, an intracellular signal transduction mechanism that
plays a critical role in the production and activity of many
proinflammatory mediators in macrophages (24, 25). p38
MAPK is expressed in the brain, but it is not known
whether it participates in the mediation of the systemic an-
tiinflammatory effects of CNI-1493,  -MSH, or nonste-
roidal antiinflammatory drugs (26–28).
Administration of CNI-1493 activates vagus nerve firing
(10), and electrical stimulation of the distal end of
transected vagus nerves recapitulates the central antiinflam-
matory activity of CNI-1493 (5). Here we show that elec-
trical stimulation of intact vagus nerves also recapitulates
the antiinflammatory action of CNI-1493, attenuates LPS-
induced systemic TNF release, and TNF synthesis in the
heart and prevents the development of endotoxin-induced
shock. The protective effects of vagus nerve stimulation
were partially dependent on stimulus voltage, but not nerve
laterality. No significant differences were observed be-
tween left or right vagus stimulation with regard to protec-
Figure 3. Electrical stimulation of intact vagus nerves protects against endotoxic shock. Electrical stimulation at the indicated voltage was applied to
the exposed, intact vagus nerve of anethesized rats. Endotoxin (50–60 mg/kg, intravenously) was given 10 min after beginning electrical stimulation;
electrical stimulation was continued for an additional 10 min as shown. (A) Blood pressure responses to electrical stimulation of the intact right cervical
vagus nerve (1 V and 5 V) in the presence of endotoxemia. Note that stimulation with either 1 V or 5 V at 2 ms intervals (5 Hz) prevented the develop-
ment of significant hypotension. (B) HR responses to electrical stimulation of the intact right cervical vagus nerve (1 V and 5 V) in the presence of en-
dotoxemia. Right vagus nerve stimulation with either 1 V or 5 V was associated with a significant, voltage stimulus-dependent increase in HR, but HR
did not increase significantly in nonstimulated endotoxemic animals, despite the development of hypotension. (C) Blood pressure responses to electrical
stimulation of the intact right and left cervical vagus nerves in the presence of endotoxemia. Electrical stimulation (5V) was applied to the either the left
or right intact vagus nerves of anesthesized rats where indicated. Note that the difference in MABP between right and left cervical vagus nerve stimula-
tion was not statistically significant. (D) HR responses to right versus left vagus nerve stimulation in the presence of endotoxemia. Electrical stimulation
(5V) was applied to the either the left or right intact vagus nerves of anesthesized rats, where indicated.787 Bernik et al.
tion against endotoxin-induced shock, demonstrating that
stimulation of either vagus nerve is effective. Electrical
stimulation of the vagus nerve was associated with in-
creased heart rates that correlated to the applied voltage.
Although it may seem paradoxical that vagus verve stimula-
tion is associated with the development of tachycardia
(instead of bradycardia), when the endotoxin-induced
changes in heart rate are considered in the context of ongo-
ing hypotension, the observed tachycardia actually reflects
normalization of an adaptive stress response in the vagus
nerve–stimulated animals.
It is well established that tissue macrophages are the pri-
mary source of increased serum TNF levels during endo-
toxemia, but recent studies suggest that production of TNF
by cardiac myocytes contributes to the development of myo-
cardial depression and shock (13). TNF has been impli-
cated in the development of cardiac failure secondary to
septic cardiomyopathy, biventricular dysfunction, and pul-
monary edema (29). The vagus nerve innervates the heart
through two cervical branches; the right vagus regulates
HR primarily through modulation of the sinoatrial node,
and the left branch influences conduction primarily through
the atrioventricular node. The observation that direct vagus
nerve stimulation inhibits cardiac TNF raises the possibility
that this strategy should be explored further for regulating
cardiac TNF levels in vivo. Vagus nerve stimulation is clin-
ically approved as therapy for epilepsy and depression and is
associated with minimal morbidity. Surgically implanted
vagus nerve stimulating devices are widely used, but it is
not known at present whether stimulation of the intact va-
gus nerve in humans influences proinflammatory cytokines
in liver, heart, or blood, or whether this modality can be
used to treat cytokine-mediated inflammatory diseases (e.g.,
rheumatoid arthritis or inflammatory bowel disease).
Two major considerations are raised by this study. First,
it now appears that the central neural mechanism of CNI-
1493 represents a previously unrecognized method for sup-
pressing systemic inflammation. Prior to these studies, it
was certainly not anticipated that a drug which inhibits p38
MAPK signaling would be 100,000-fold more effective as
an inhibitor of TNF in vivo through a distinct, neural-
based mechanism. A better understanding of the underly-
ing neural signaling pathways and associated receptors that
activate the cholinergic antiinflammatory pathway may
yield new insights into the design of agents that act cen-
trally to suppress systemic inflammation. Second, electrical
stimulation of the intact vagus nerve inhibits excessive sys-
temic inflammation; this activity is both tissue specific and
efficacious. Thus, the cholinergic antiinflammatory path-
way is uniquely positioned to effectively counterregulate fi-
nal common pathways to tissue injury which converge on
the activity of proinflammatory cytokines.
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